216 related articles for article (PubMed ID: 15378504)
1. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
Makiyama A; Itoh Y; Kasahara A; Imai Y; Kawata S; Yoshioka K; Tsubouchi H; Kiyosawa K; Kakumu S; Okita K; Hayashi N; Okanoue T
Cancer; 2004 Oct; 101(7):1616-22. PubMed ID: 15378504
[TBL] [Abstract][Full Text] [Related]
2. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
5. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
6. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.
Basso M; Torre F; Picciotto A
Cancer; 2005 Jun; 103(12):2654-5; author reply 2655. PubMed ID: 15884032
[No Abstract] [Full Text] [Related]
8. Resected cases of hepatocellular carcinoma detected after interferon therapy for chronic hepatitis C.
Kubo S; Nishiguchi S; Tamori A; Hirohashi K; Tanaka H; Tsukamoto T; Shuto T; Kuroki T; Kinoshita H
Hepatogastroenterology; 2000; 47(34):1100-2. PubMed ID: 11020887
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
10. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
11. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up study of sustained biochemical responders with interferon therapy.
Shindo M; Hamada K; Oda Y; Okuno T
Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
[TBL] [Abstract][Full Text] [Related]
13. Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B.
Tangkijvanich P; Thong-ngam D; Mahachai V; Kladchareon N; Suwangool P; Kullavanijaya P
Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):452-8. PubMed ID: 11944697
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C.
Enokimura N; Shiraki K; Kawakita T; Saitou Y; Inoue H; Okano H; Yamamoto N; Deguchi M; Sakai T; Ohmori S; Fujikawa K; Murata K; Niki Y; Nakano T
Anticancer Res; 2003; 23(1B):593-6. PubMed ID: 12680152
[TBL] [Abstract][Full Text] [Related]
15. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
16. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.
Uenishi T; Nishiguchi S; Tanaka S; Yamamoto T; Takemura S; Kubo S
J Surg Oncol; 2008 Oct; 98(5):358-62. PubMed ID: 18646001
[TBL] [Abstract][Full Text] [Related]
17. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.
Kawamura Y; Arase Y; Ikeda K; Hirakawa M; Hosaka T; Kobayashi M; Saitoh S; Yatsuji H; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
Am J Med; 2010 Oct; 123(10):951-956.e1. PubMed ID: 20920698
[TBL] [Abstract][Full Text] [Related]
18. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C.
Sanefuji K; Kayashima H; Iguchi T; Sugimachi K; Yamashita Y; Yoshizumi T; Soejima Y; Nishizaki T; Taketomi A; Maehara Y
J Surg Oncol; 2009 Jan; 99(1):32-7. PubMed ID: 18985618
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma developed in a patient with chronic hepatitis C after the disappearance of hepatitis C virus due to interferon therapy.
Inoue M; Ohhira M; Ohtake T; Matsumoto A; Kawashima T; Fujimoto Y; Hasebe C; Ono M; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2554-60. PubMed ID: 10522040
[TBL] [Abstract][Full Text] [Related]
20. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response.
Imai Y; Kasahara A; Tanaka H; Okanoue T; Hiramatsu N; Tsubouchi H; Yoshioka K; Kawata S; Tanaka E; Hino K; Hayashi K; Tamura S; Itoh Y; Sasaki Y; Kiyosawa K; Kakumu S; Okita K; Hayashi N
J Gastroenterol; 2004 Nov; 39(11):1069-77. PubMed ID: 15580400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
